NCT02789150View on ClinicalTrials.gov

Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

January 11, 2018

Study Completion Date

January 11, 2018

Conditions

Hepatorenal Syndrome

Interventions

DRUG

Norepinephrine (Levophed)

Titrate norepinephrine to MAP 65-70

DRUG

Norepinephrine (Levophed)

Titrate norepinephrine to MAP 85 or greater

Trial Locations (1)

40202

University of Louisville, Louisville

All Listed Sponsors

lead

University of Louisville

OTHER

NCT02789150 - Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg | Biotech Hunter | Biotech Hunter